Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study

References

• Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397:1301–1315.
   PubMed Web of Science ®Google Scholar
• Mosca M, Hong J, Hadeler E, et al. The role of IL-17 cytokines in psoriasis. Immunotargets Ther. 2021;10:409–418.
   PubMed Web of Science ®Google Scholar
• Craig S, Warren RB. Ixekizumab for the treatment of psoriasis: up-to-date. Expert Opin Biol Ther. 2020;20:549–557.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Andersen YMF, Halling-Overgaard AS, et al. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. J Eur Acad Dermatol Venereol. 2020;34:39–46.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Lebwohl MG, Mabuchi T, et al. Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2021;85:360–368.
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica. 1978;157:238–244.
   PubMedGoogle Scholar
• Lockshin B, Cronin A, Harrison RW, et al. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the corrona psoriasis registry. Dermatol Ther. 2021;34:e14808.
   PubMed Web of Science ®Google Scholar
• Cariti C, Dapavo P, Mastorino L, et al. Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients. J Eur Acad Dermatol Venereol. 2022;36:e233–235.
   PubMed Web of Science ®Google Scholar
• Malagoli P, Dapavo P, Pavia G, et al. Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: a 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis). Dermatol Ther. 2022;35:e15608.
   PubMed Web of Science ®Google Scholar
• Torres T, Puig L, Vender R, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;30:567–579.
   Google Scholar
• Ohata C, Ohyama B, Katayama E, et al. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: a single-center experience. J Dermatol. 2020;47:405–408.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Shi N, Burge R, et al. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab. J Am Acad Dermatol. 2020;82:927–935.
   PubMed Web of Science ®Google Scholar
• Caldarola G, Mariani M, Pirro F, et al. Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice. Expert Opin Biol Ther. 2021;21:279–286.
   PubMed Web of Science ®Google Scholar
• van den Reek JMPA, van Vugt LJ, van Doorn MBA, et al. Initial results of secukinumab drug survival in patients with psoriasis: a multicentre daily practice cohort study. Acta Dermatol Venereol. 2018;98(7):648–654. DOI:10.2340/00015555-2900
   PubMed Web of Science ®Google Scholar
• Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178:509–519.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Bryld LE, Skov L. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;81:173–178.
   PubMed Web of Science ®Google Scholar
• Magdaleno-Tapial J, Carmena-Ramón R, Valenzuela-Oñate C, et al. Efficacy and safety of ixekizumab in a real-life practice: a retrospective bicentric study. Actas Dermosifiliogr (Engl Ed). 2019;110:585–589.
   PubMed Web of Science ®Google Scholar
• Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, et al. Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: real-world practice. Dermatol Ther. 2020;33:e14202.
   PubMed Web of Science ®Google Scholar
• Pirro F, Caldarola G, Chiricozzi A, et al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41:917–925.
   PubMed Web of Science ®Google Scholar
• Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience. Ther Adv Chronic Dis. 2018;9:147–158.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Zangrilli A, Bavetta M, et al. Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. J Eur Acad Dermatol Venereol. 2017;31:304–311.
   PubMed Web of Science ®Google Scholar
• Mourad A, Straube S, Armijo-Olivo S, et al. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019;181:450–458.
   PubMed Web of Science ®Google Scholar
• ] Warren RB, Marsden A, Tomenson B, et al.; PSORT Consortium and on behalf of the BADBIR Study Group. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019;180:1069–1076. DOI:10.1111/bjd.16776
   PubMed Web of Science ®Google Scholar
• Zangrilli A, Caldarola G, Bernardini N, et al. Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy. Expert Opin Biol Ther. 2021;21:1291–1298.
   PubMed Web of Science ®Google Scholar
• Lanna C, Zangrilli A, Bavetta M, et al. Efficacy and safety of adalimumab in difficult-to-treat psoriasis. Dermatol Ther. 2020;33:e13374.
   PubMed Web of Science ®Google Scholar
• Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther. 2020;20:665–672.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Conrad C, Vender R, et al. Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab. Br J Dermatol. 2021;185:865–867.
   PubMed Web of Science ®Google Scholar
• Megna M, Caiazzo G, Parisi M, et al. Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role? Clin Exp Dermatol. 2022;47:918–925.
   PubMed Web of Science ®Google Scholar